Payment overview · 2025
General Payments
$1,602.31
103 reported records · 22 companies
Healthcare provider profile · identity verified
Peter P Barcas, D.O.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · NEPTUNE, NJ · NPI 1407838972
Verified facts
What the public records show
CMS Open Payments records show Peter P Barcas, D.O. received $1,602.31 in general payments during 2025 across 103 reported records.
PFIZER INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Soliris by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $394.88 | 24.6% | 32 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $344.58 | 21.5% | 20 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $261.29 | 16.3% | 16 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $82.99 | 5.2% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $57.09 | 3.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.82 | 3.4% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.69 | 3.2% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $36.02 | 2.2% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$31.90 | 2.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $31.02 | 1.9% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.63 | 1.9% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $29.37 | 1.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.75 | 1.8% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $21.99 | 1.4% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $21.79 | 1.4% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.31 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.34 | 1.2% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.86 | 1.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $16.84 | 1.1% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $16.79 | 1.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.58 | 1.0% | 1 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.78 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,602.31 | 103 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $347.48 | 29 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $325.75 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $323.46 | 27 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $307.81 | 18 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $261.29 | 16 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $82.99 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $57.09 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $57.09 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $54.82 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $54.82 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $51.69 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $47.40 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $47.40 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $21.79 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 312 | 92 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 139 | 45 |
| Gabapentin | Gabapentin | 131 | 40 |
| Memantine Hcl | Memantine Hcl | 116 | 44 |
| Levetiracetam | Levetiracetam | 111 | 29 |
| Topiramate | Topiramate | 70 | 18 |
| Primidone | Primidone | 58 | 12 |
| Oxcarbazepine | Oxcarbazepine | 56 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 55 | 14 |
| Lacosamide | Lacosamide | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Carbamazepine Er | Carbamazepine | 47 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Pregabalin | Pregabalin | 36 | 16 |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Zonisamide | Zonisamide | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 20 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Soliris | Eculizumab | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,602.31 · 103 records | PFIZER INC. | ACTHAR, AMYVID, AUSTEDO XR, Bafiertam, Dysport, FYCOMPA, Gamunex-C, General - DBS, Hizentra, INGREZZA, KESIMPTA, KISUNLA, NEURACEQ, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, QULIPTA, Rystiggo, SYMPAZAN, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYALEV, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Alexion Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error